Trial
NCT01773395
GVAX vs. Placebo for MDS/AML After Allo HSCT
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Massachusetts General Hospital; Beth Israel Deaconess Medical Center
Condition
Myelodysplastic Syndrome
Intervention
GVAX
Why stopped
Recommendation by the Data and Safety Monitoring Board due to efficacy concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-18